Zacks Investment Research Upgrades Kura Oncology, Inc. (KURA) to Buy
Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a research note published on Monday morning. They currently have $17.00 price objective on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other equities analysts have also recently commented on the company. Cowen and Company initiated coverage on Kura Oncology in a report on Thursday, September 7th. They issued an outperform rating for the company. ValuEngine raised Kura Oncology from a sell rating to a hold rating in a report on Friday, September 8th. Oppenheimer Holdings, Inc. set a $16.00 price target on Kura Oncology and gave the company a buy rating in a report on Wednesday, June 14th. Citigroup Inc. set a $13.00 price target on Kura Oncology and gave the company a buy rating in a report on Tuesday, August 8th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $16.00.
Kura Oncology (NASDAQ KURA) opened at 14.00 on Monday. The firm’s market cap is $279.83 million. Kura Oncology has a 52-week low of $4.00 and a 52-week high of $15.30. The company’s 50-day moving average price is $10.39 and its 200-day moving average price is $9.34.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. Analysts predict that Kura Oncology will post ($1.53) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Kura Oncology, Inc. (KURA) to Buy” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-investment-research-upgrades-kura-oncology-inc-kura-to-buy-2/1611800.html.
Several institutional investors and hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. raised its holdings in shares of Kura Oncology by 14.7% in the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after buying an additional 1,600 shares in the last quarter. Nationwide Fund Advisors raised its holdings in shares of Kura Oncology by 66.2% in the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock worth $240,000 after buying an additional 10,258 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Kura Oncology in the 2nd quarter worth approximately $102,000. Segantii Capital Management Ltd acquired a new position in shares of Kura Oncology in the 1st quarter worth approximately $120,000. Finally, Rhumbline Advisers acquired a new position in shares of Kura Oncology in the 2nd quarter worth approximately $131,000. 39.07% of the stock is owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.